Raajit Rampal

1 month ago | onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani

OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss key accomplishments in the myeloproliferative neoplasm (MPN) space, highlighting pivotal developments that have shaped clinical practice, and share their excitement for 2025, including areas primed for significant progress and goals for the coming year. Video content above is prompted by the following:What accomplishments in the MPN space are you most proud of? Which developments stand out as pivotal in shaping clinical practice?

1 month ago | onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani

OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss noteworthy updates in myelofibrosis (MF) from ASH 2024, share their views on the future of MF treatment, offer clinical pearls for community oncologists, and highlight emerging pathways and targets they are excited about for MF management. Video content above is prompted by the following:Dr Kuykendall to faculty: What outstanding updates in MF from ASH 2024 are noteworthy?

1 month ago | onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani

OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss studies aimed at combating dose-dependent anemia as a consequence of Janus kinase inhibitors (JAKi) treatment and share their thoughts on potential strategies to address this challenge. Video content above is prompted by the following:Dr Kuykendall to faculty: Dose-dependent anemia can be a consequence of treatment with JAKi. What are your thoughts on studies aimed at combating this challenge?

2 months ago | onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani

Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and PracticePanelists discuss the types of questions that real-world (RW) data can answer in comparison to with clinical trial data, and how it they can complement clinical findings in treatment decision-making.

2 months ago | onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani

Panelists discuss data from the FREEDOM2 trial and its sub-analysis on low platelet count with fedratinib (FEDR), as well as the pooled analysis of the COMFORT-I/-II trials on ruxolitinib (RUX) for myelofibrosis.